Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis
Summary: Cagrilintide and retatrutide are investigational injectable medicines being studied for obesity and type 2 diabetes in men, targeting multiple hormonal pathways to reduce appetite, improve blood glucose control, and increase energy expenditure, but neither is currently licensed in the UK
That is encouraging because it suggests stronger fat loss does not necessarily come with disproportionately worse lean-mass loss
However, the clinical impact of partial gastric slowing without strong appetite suppression remains unclear
Many Canadians use their family physician for routine labs or access walk-in clinics that offer direct-pay bloodwork panels
Retatrutide is a synthetic peptide and investigational triple-receptor agonist peptide studied for metabolic research involving GLP-1, GIP, and glucagon receptor pathways